Brainstem cavernous malformations (BSCMs) are vascular lesions that can lead to significant neurological symptoms due to their location and the potential for hemorrhage. Managing these ...

Cavernous malformations, also known as "cavernous angiomas," "cavernous hemangiomas" or just "cavernomas" are clusters of tightly packed abnormal blood vessels surrounded by normal brain tissue.

Cerebral cavernous malformations (CCMs) are vascular abnormalities in the brain characterized by clusters of dilated blood vessels that can lead to various neurological symptoms, including ...

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations ... Notably, patients with brainstem lesions, typically unresponsive ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Cerebral vascular malformations (CVMs), including cerebral arteriovenous malformations (AVMs) and cavernous malformations (CCMs), have long posed challenges due to their complex origins and severe ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...

Children with cavernous malformations face unique treatment challenges due to factors such as the malformation's location, size, risk of bleeding, and the complexities of pediatric tissue development.